Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAREON-9: BI 764532 + Chemotherapy in Relapsed/Refractory SCLC
NCT05990738Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2024
- Primary completion
- Mar 2027
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of obrixtamig in small cell lung cancer (SCLC) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Dose Limiting Toxicities at 9 weeks and Adverse Events at 36 months. Started Feb 2024; status: active, not recruiting.
02
Drugs
obrixtamig
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05990738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05990738.